5-[[(2-氨基乙基)硫代]甲基]-N-甲基-2-呋喃甲胺 | 66356-54-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 5-[[(2-氨基乙基)硫代]甲基]-N-甲基-2-呋喃甲胺
• 英文名称: 2-[[[5-(methylamino)methyl-2-furanyl]methyl]thio]ethanamine
• 英文别名: 5-[[(2-aminoethyl)thio]methyl]-N-methyl-2-furanmethanamine；2-[(5-methylaminomethyl-furan-2-yl)methylthio]ethylamine；2-[[5-(methylaminomethyl)furan-2-yl]methylsulfanyl]ethanamine
• CAS: 66356-54-5
• 化学式: C₉H₁₆N₂OS
• 分子量: 200.305
• InChiKey: JRQYKULIUYUIQS-UHFFFAOYSA-N

物化性质

• 沸点：
  302.2±42.0 °C(Predicted)
• 密度：
  1.107±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于丙酮、二氯甲烷、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  76.5
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-[[(2-氨基乙基)硫代]甲基]-N-甲基-2-呋喃甲胺 、 异氰酸甲酯 在 氨 作用下， 以 乙腈 为溶剂， 生成 N-[2-[[[5-(methylamino)methyl-2-furanyl]methyl]thio]ethyl]-N'-methylurea
  参考文献：
  名称：

  Aminoalkyl furan derivatives

  摘要：

  通式I的化合物：##STR1##及其生理上可接受的盐和N-氧化物和水合物，其中R.sub.1和R.sub.2可以相同也可以不同，代表氢、较低的烷基、环烷基、较低的烯基、芳基烷基或被氧原子或基团##STR2##中断的较低烷基，其中R.sub.4代表氢或较低烷基或R.sub.1和R.sub.2可以与它们连接的氮原子一起形成可能包含其他杂原子O和##STR3##的杂环环，R.sub.3是氢、较低烷基、较低烯基或烷氧基烷基；X是--CH.sub.2--、O或S；Y代表.dbd. S、.dbd. O、.dbd. NR.sub.5或.dbd. CHR.sub.6；Alk表示由1到6个碳原子的直链或支链烷基链；R.sub.5是H、硝基、氰基、较低烷基、芳基、烷基磺酰基或芳基磺酰基；R.sub.6代表硝基、芳基磺酰基或烷基磺酰基；M是从2到4的整数；N是1或2；或当X.dbd.S或--CH.sub.2--时，n为零、1或2。这些化合物具有H.sub.2-拮抗活性。还提供了其生产中间体。

  公开号：

  US04128658A1

文献信息

• Amine derivatives and pharmaceutical compositions containing them
  申请人：Glaxo Group Limited

  公开号：US04233302A1

  公开（公告）日：1980-11-11

  The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, N-oxides, hydrates and bioprecursors thereof, in which Y represents .dbd.O, .dbd.S, .dbd.CHNO.sub.2 or .dbd.NR.sub.3 where R.sub.3 represents hydrogen, nitro, cyano, lower alkyl, aryl, lower alkylsulphonyl or arylsulphonyl; R.sub.1 and R.sub.2, which may be the same or different, each represent hydrogen lower alkyl, cycloalkyl, lower alkenyl, aralkyl, hydroxy, lower trifluoroalkyl, lower alkyl substituted by hydroxy, lower alkoxy, amine, lower alkylamino or dialkylamino, or R.sub.1 and R.sub.2 together with the nitrogen atom to which they are attached form a 5 to 7 membered heterocyclic ring which may contain other heteroatoms or the group ##STR2## where R.sub.4 represents hydrogen or lower alkyl; Q represents a furan or thiophen ring in which incorporation into the rest of the molecule is through bonds at the 2- and 5-positions, or a benzene ring in which incorporation into the rest of the molecule is through bonds at the 1- and 3- or 1- and 4-positions; X represents --CH.sub.2, --O-- or --S--; n represents zero, 1 or 2; m represents 2, 3 or 4; Alk represents a straight chain alkylene group of 1 to 3 carbon atoms; (except that n is not zero when X is oxygen and Q is a furan or thiophen ring system) q represents 2, 3 or 4 or can additionally represent zero or 1 when E is a --CH.sub.2 -group; p represents zero, 1 or 2; E represents --CH.sub.2 --, --O-- or --S--; and Z represents a monocyclic 5 or 6 membered carbocyclic or heterocyclic aromatic ring which may be optionally substituted by one or more groups or Z represents the group ##STR3## where Q' represents any of the rings defined for Q; Alk' represents any of the groups defined for Alk; and R.sub.5 and R.sub.6, which may be the same or different, each represent any of the groups defined for R.sub.1 and R.sub.2 ; (except that p is not zero when E is oxygen and Q' or Z is a furan or thiophen ring system). The compounds of formula (I) show pharmacological activity as selective histamine H.sub.2 -antagonists.

  该发明涉及通式（I）的化合物##STR1##及其生理上可接受的盐、N-氧化物、水合物和生物前体，其中Y代表.dbd.O、.dbd.S、.dbd.CHNO.sub.2或.dbd.NR.sub.3，其中R.sub.3代表氢、硝基、氰基、较低的烷基、芳基、较低的烷基磺酰基或芳基磺酰基；R.sub.1和R.sub.2，可能相同也可能不同，每个代表氢、较低的烷基、环烷基、较低的烯基、芳基烷基、羟基、较低三氟甲基、被羟基、较低的烷氧基、胺基、较低的烷基胺基或二烷基胺基取代的较低烷基，或者R.sub.1和R.sub.2与它们连接的氮原子一起形成一个含有其他杂原子的5至7成员杂环，或者组##STR2##其中R.sub.4代表氢或较低的烷基；Q代表将其并入分子其余部分的2-和5-位置键合的呋喃或噻吩环，或者将其并入分子其余部分的1-和3-或1-和4-位置键合的苯环；X代表--CH.sub.2、--O--或--S--；n表示零、1或2；m表示2、3或4；Alk代表1至3个碳原子的直链烷基基团；（除非当X为氧且Q为呋喃或噻吩环系时n不为零）q表示2、3或4，或者当E为--CH.sub.2-基团时还可以表示零或1；p表示零、1或2；E代表--CH.sub.2--、--O--或--S--；Z代表可以选择地被一个或多个基团取代的单环5或6成员碳环或杂环芳香环，或者Z代表组##STR3##其中Q'代表Q定义的任何环之一；Alk'代表Alk定义的任何基团；R.sub.5和R.sub.6，可能相同也可能不同，每个代表R.sub.1和R.sub.2定义的任何基团；（除非当E为氧且Q'或Z为呋喃或噻吩环系时p不为零）。通式（I）的化合物显示作为选择性组胺H.sub.2-拮抗剂的药理活性。
• N'-Derivatives of N-(2-mercapto-ethyl)-2-nitro-1,1-ethenediamine
  申请人：Allen & Hansbury, Limited

  公开号：US04169855A1

  公开（公告）日：1979-10-02

  Compounds of the general formula: ##STR1## in which R.sub.3 is hydrogen, lower alkyl, lower alkenyl or alkoxyalkyl. These compounds are useful in the preparation of novel aminoalkyl furan derivatives having a selective action on histamine receptors.

  一般式为##STR1##的化合物，其中R.sub.3为氢、低级烷基、低级烯基或烷氧基烷基。这些化合物在制备具有对组胺受体选择性作用的新型氨基烷基呋喃衍生物中非常有用。
• Furan derivatives having selective action on histamine receptors
  申请人：Allen & Hanburys Limited

  公开号：US04255440A1

  公开（公告）日：1981-03-10

  Compounds of the general formula I: ##STR1## and physiologically acceptable salts thereof and N-oxides and hydrates, in which R.sub.1 and R.sub.2 which may be the same or different represent hydrogen, lower alkyl, cycloalkyl, lower alkenyl, aralkyl or lower alkyl interrupted by an oxygen atom or a group ##STR2## in which R.sub.4 represents hydrogen or lower alkyl or R.sub.1 and R.sub.2 may, together with the nitrogen atom to which they are attached, form a heterocyclic ring which may contain other heteroatoms selected from O and ##STR3## R.sub.3 is hydrogen, lower alkyl, lower alkenyl or alkoxyalkyl; X is --CH.sub.2 --, O-- or --S--; Y represents .dbd.S, .dbd.O, .dbd.NR.sub.5 or .dbd.CHR.sub.6 ; Alk denotes a straight or branched alkylene chain of 1 to 6 carbon atoms; R.sub.5 is H, nitro, cyano, lower alkyl, aryl, alkylsulphonyl, or arylsulphonyl; R.sub.6 represents nitro, arylsulphonyl or alkylsulphonyl; m is an integer from 2 to 4; and n is 1 or 2; or when X is --S-- or --CH.sub.2 --, n is zero, 1 or 2. These compounds have H.sub.2 -antagonist activity. Intermediates in the production thereof are also provided.

  一般式为I的化合物：## STR1 ##及其生理上可接受的盐和N-氧化物和水合物，其中R.sub.1和R.sub.2可能相同或不同，代表氢，低烷基，环烷基，低烯基，芳基烷基或被氧原子或群体## STR2 ##中断的低烷基，其中R.sub.4代表氢或低烷基，或R.sub.1和R.sub.2可以与它们附着的氮原子一起形成可能包含其他杂原子（如O和## STR3 ##）的杂环，R.sub.3为氢，低烷基，低烯基或烷氧基烷基；X为--CH.sub.2 --，O--或--S--；Y代表.dbd.S，.dbd.O，.dbd.NR.sub.5或.dbd.CHR.sub.6；Alk表示1到6个碳原子的直链或支链烷基链；R.sub.5为H，硝基，氰基，低烷基，芳基烷基，烷基磺酰基或芳基磺酰基；R.sub.6代表硝基，芳基磺酰基或烷基磺酰基；m为2至4的整数；n为1或2；或当X为--S--或--CH.sub.2 --时，n为零，1或2。这些化合物具有H.sub.2-拮抗剂活性。还提供了其生产的中间体。
• Aminoalkylthiophene derivatives as histamine H.sub.2 -antagonists
  申请人：Glaxo Group Limited

  公开号：US04304780A1

  公开（公告）日：1981-12-08

  The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, N-oxides, hydrates and bioprecursors thereof, in which Y represents .dbd.O, .dbd.S, .dbd.CHNO.sub.2 or .dbd.NR.sub.3 where R.sub.3 represents hydrogen, nitro, cyano, lower alkyl, aryl, lower alkylsulphonyl or arylsulphonyl; R.sub.1 and R.sub.2, which may be the same or different, each represent hydrogen lower alkyl, cycloalkyl, lower alkenyl, aralkyl, hydroxy, lower trifluoroalkyl, lower alkyl substituted by hydroxy, lower alkoxy, amine, lower alkylamino or dialkylamino, or R.sub.1 and R.sub.2 together with the nitrogen atom to which they are attached form a 5 to 7 membered heterocyclic ring which may contain other heteroatoms or the group ##STR2## where R.sub.4 represents hydrogen or lower alkyl; Q represents a furan or thiophen ring in which incorporation into the rest of the molecule is through bonds at the 2- and 5-positions, or a benzene ring in which incorporation into the rest of the molecule is through bonds at the 1- and 3- or 1- and 4-positions; X represents --CH.sub.2 --, --O-- or --S--; n represents zero, 1 or 2; m represents 2, 3 or 4; Alk represents a straight chain alkylene group of 1 to 3 carbon atoms; (except that n is not zero when X is oxygen and Q is a furan or thiophen ring system) q represents 2, 3 or 4 or can additionally represent zero or 1 when E is a --CH.sub.2 --group; p represents zero, 1 or 2; E represents --CH.sub.2 --, --O-- or --S--; and Z represents a monocyclic 5 or 6 membered carbocyclic or heterocyclic aromatic ring which may be optionally substituted by one or more groups or Z represents ##STR3## where Q' represents any of the rings defined for Q; Alk' represents any of the groups defined for Alk; and R.sub.5 and R.sub.6, which may be the same or different, each represent any of the groups defined for R.sub.1 and R.sub.2 ; (except that p is not zero when E is oxygen and Q' or Z is a furan or thiophen ring system) The compounds of formula (I) show pharmacological activity as selective histamine H.sub.2 -antagonists.

  该发明涉及通式（I）的化合物及其生理上可接受的盐、N-氧化物、水合物和生物前体，其中Y代表.dbd.O、.dbd.S、.dbd.CHNO.sub.2或.dbd.NR.sub.3，其中R.sub.3代表氢、硝基、氰基、低碳基、芳基、低碳基磺酰基或芳基磺酰基；R.sub.1和R.sub.2，可相同可不同，各代表氢、低碳基、环烷基、低烯基、芳基烷基、羟基、低三氟甲基、被羟基取代的低碳基、低烷氧基、胺基、低烷基氨基或二烷基氨基，或R.sub.1和R.sub.2与它们所附着的氮原子共同形成一个含有其他杂原子或基团的5到7成员杂环，其中R.sub.4代表氢或低碳基；Q代表通过2-和5-位置的键结合到分子其余部分的呋喃或噻吩环，或通过1-和3-或1-和4-位置的键结合到分子其余部分的苯环；X代表--CH.sub.2 --、--O--或--S--；n代表零、1或2；m代表2、3或4；Alk代表1到3个碳原子的直链烷基；（除非X为氧且Q为呋喃或噻吩环系，否则n不为零）q代表2、3或4，或当E为--CH.sub.2 --基团时，还可以表示零或1；p代表零、1或2；E代表--CH.sub.2 --、--O--或--S--；Z代表可以选择性地被一个或多个基团取代的单环5或6成员碳环或杂环芳香环，或Z代表##STR3##其中Q'表示为Q定义的任何环；Alk'表示为Alk定义的任何基团；R.sub.5和R.sub.6，可相同可不同，各代表R.sub.1和R.sub.2定义的任何基团；（除非E为氧且Q'或Z为呋喃或噻吩环系，否则p不为零）。通式（I）的化合物表现出选择性组胺H.sub.2-拮抗剂的药理活性。
• Amine derivatives, their preparation and pharmaceutical compositions containing them
  申请人：GLAXO GROUP LIMITED

  公开号：EP0002930A1

  公开（公告）日：1979-07-11

  The invention relates to compounds of the general formula (I) and physiologically acceptable salts, N-oxides, hydrates and bioprecursors thereof, in which Y represents =0, =S, =CHNO2 or =NR3 where R3 represents hydrogen, nitro, cyano, lower alkyl, aryl, lower alkylsulphonyl or arylsulphonyl; R1 and R2, which may be the same or different, each represent hydrogen lower alkyl, cycloalkyl, lower alkenyl, aralkyl, hydroxy, lower trifluoroalkyl, lower alkyl substituted by hydroxy, lower alkoxy, amine, lower alkylamino or dialkylamino, or R1 and R2 together with the nitrogen atom to which they are attached form a 5 to 7 membered heterocyclic ring which may contain other heteroatoms or the group where R4 represents hydrogen or lower alkyl; Q represents a furan or thiophen ring in which incorporation into the rest of the molecule is through bonds at the 2- and 5-positions, or a benzene ring in which incorporation into the rest of the molecule is through bonds at the 1- and 3- or 1- and 4-positions; X represents-CH2-,-O-or-S-; n represents zero, 1 or 2; m represents 2, 3 or 4; Alk represents a straight chain alkylene group of 1 to 3 carbon atoms; (except that n is not zero when X is oxygen and Q is a furan or thiophen ring system) q represents 2, 3, or 4 or can additionally represent zero or 1 when E is a -CH2-group; p represents zero, 1 or 2; E represents-CN2-,-O- or -S-; and Z represents a monocyclic 5 or 6 membered carbocyclic or heterocyclic aromatic ring which may be optionally substituted by one or more groups or Z represents the group where Q' represents any of the rings defined for Q; Alk' represents any of the groups defined for Alk: and R5 and R6, which may be the same or different, each represent any of the groups defined for R1 and R2; (except that p is not zero when E is oxygen and Q' or Z is a furan or thiophen ring system. The compounds of formula (I) show pharmacological activity as selective histamine H2-antagonists.

  本发明涉及通式(I)化合物 及其生理学上可接受的盐、N-氧化物、水合物和生物前体，其中 Y 代表 =0、=S、=CHNO2 或 =NR3 其中 R3 代表氢、硝基、氰基、低级烷基、芳基、低级烷基磺酰基或芳基磺酰基；R1 和 R2（可以相同或不同）分别代表氢、低级烷基、环烷基、低级烯基、芳烷基、羟基、低级三氟烷基、被羟基取代的低级烷基、低级烷氧基、胺、低级烷基氨基或二烷基氨基，或 R1 和 R2 与它们所连接的氮原子一起形成一个 5 至 7 个成员的杂环，该杂环可能含有其他杂原子或基团 其中 R4 代表氢或低级烷基；Q 代表呋喃环或噻吩环，通过 2 位和 5 位的键与分子的其余部分结合，或代表苯环，通过 1 位和 3 位或 1 位和 4 位的键与分子的其余部分结合； X 代表-CH2-、-O-或-S-； n 代表零、1 或 2 m 代表 2、3 或 4； Alk 代表 1 至 3 个碳原子的直链亚烷基；（但当 X 是氧且 Q 是呋喃或噻吩环系时，n 不为零） q 代表 2、3 或 4，当 E 为-CH2-基团时，可另外代表 0 或 1； p 代表 0、1 或 2； E 代表-CN2-、-O-或-S-；以及 Z 代表可被一个或多个基团任选取代的单环 5 或 6 位碳环或杂环芳香环，或 Z 代表以下基团 其中 Q' 代表为 Q 定义的任何环； Alk' 代表为 Alk 定义的任何基团：以及 R5 和 R6（可以相同或不同）各自代表为 R1 和 R2 定义的任何基团；（但当 E 为氧，且 Q' 或 Z 为呋喃或噻吩环系时，p 不为零。 式（I）化合物具有选择性组胺 H2- 拮抗剂的药理活性。